Overview

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Phase:
PHASE3
Details
Lead Sponsor:
Vega Therapeutics, Inc